Dear traders and followers,
the UnitedHealth group chart has been in a clear downtrend since mid-April, with a potential bottom forming around $250. If this level breaks, the next strong support lies in the $200–220 zone. This is my preferred entry zone
A stop-loss below the COVID crash low is advisable to manage risk. The stop-loss should be mental and only triggered if a weekly candle closes below the low.
Fundamentally the stock faces uncertainty due to ongoing lawsuits and potential policy changes under a Trump administration.
While UNH remains a strong long-term investment, the road back to the $400 level will likely be slow and challenging, requiring patience and resilience from investors.
the UnitedHealth group chart has been in a clear downtrend since mid-April, with a potential bottom forming around $250. If this level breaks, the next strong support lies in the $200–220 zone. This is my preferred entry zone
A stop-loss below the COVID crash low is advisable to manage risk. The stop-loss should be mental and only triggered if a weekly candle closes below the low.
Fundamentally the stock faces uncertainty due to ongoing lawsuits and potential policy changes under a Trump administration.
While UNH remains a strong long-term investment, the road back to the $400 level will likely be slow and challenging, requiring patience and resilience from investors.
The analyses provided are for informational purposes only and do not constitute financial advice or recommendations to buy or sell anything. The information presented is based on personal research and interpretation.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
The analyses provided are for informational purposes only and do not constitute financial advice or recommendations to buy or sell anything. The information presented is based on personal research and interpretation.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.